Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PECS Block vs Local Infiltration for Partial Mastectomy
NCT04824599Completed
- Sponsor
- Centralsjukhuset Karlstad
- Start
- Feb 2021
- Primary completion
- May 2022
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Randomised, open-label trial of ropivacaine in breast cancer (2 arms), sponsored by Centralsjukhuset Karlstad. Primary endpoints: Maximal pain in PACU measured with 11 point numerical rating scale (NRS) at 4 hours and Intraoperative fentanyl use at 3 hours. Started Feb 2021; status: completed.
02
Drugs
ropivacaine
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04824599.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04824599.